China approves two experimental COVID-19 vaccines to enter clinical trials

BEIJING: China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus that killed more than 100,000 people worldwide, state media Xinhua reported on Tuesday (Apr 14).

The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.

In March, China has the green-light for another clinical trial for a coronavirus vaccine candidate developed by military-backed China’s Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio, shortly after US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health. 

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram